知镜 Cognispect · 医学文献与研究工作台

[Type 2 Macular Telangiectasia: Pathogenesis-The Interplay Between Neurodegeneration and Metabolic Changes].

Jung M, Bucher F.
Klinische Monatsblatter fur Augenheilkunde · 2026-08-27 · PMID 42660511

文献摘要

Abstract Macular telangiectasia type 2 (MacTel type 2) is a rare, chronic neurodegenerative macular disease that typically occurs bilaterally in the second half of life. Patients report paracentral scotomas and reading difficulties early in the disease course. Over time, limitations in daily life progressively increase. Abstract Although the macular vascular changes give the condition its name, MacTel type 2 is now considered a primarily neurodegenerative disease with secondary vascular changes. In a small number of patients ( Abstract Pathomechanistically, reduced serine levels lead to aberrant sphingolipid synthesis with the accumulation of neurotoxic deoxysphingolipids. This leads to degeneration of Müller cells, the retinal pigment epithelium, and photoreceptors, culminating in a breakdown of the blood-retinal barrier with secondary vascular changes. Neurodegeneration remains confined to a circumscribed area around the fovea, the MacTel zone. Abstract Therapeutically, the only established treatment in Europe at present is for secondary choroidal neovascularization, using intravitreal anti-VEGF therapy. A neuroprotective therapeutic approach, in which a novel cell-based depot system continuously releases ciliary neurotrophic factor, thereby slowing down photoreceptor degeneration, is currently approved only in the U.S. Complementary strategies to slow the underlying disease progression are urgently needed. In animal models, oral serine supplementation has been shown to slow neurodegeneration. Phase 2 and 3 clinical trials in humans are already underway, although they have not yet fully completed (ClinicalTrials.gov: NCT04907084).

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。